Audrey Roussel-Gervais

Antion Biosciences is a biotechnology company specializing in multiplex gene silencing and multi-gene expression platforms. Its in silico-designed constructs enable precise, simultaneous modification of multiple genes in a single step, ensuring that all cells carry the intended modifications. The technology is designed for safety and scalability, supporting applications in cell (ex vivo and in vivo delivery settings) and gene therapy, as well as the development of engineered cell lines, organoids, and mouse models. By seamlessly combining computational design with experimental workflows, Antion Biosciences delivers versatile, efficient, and highly adaptable solutions for both therapeutic development and preclinical research. Validated by leaders like Prof. Carl June’s lab and Allogene Therapeutics, Antion’s platform delivers: multiplex silencing of up to seven or more genes simultaneously, surpassing competitors limited to 2-3 targets It achieves high and tunable knockdown efficiency, broad cell type compatibility, and uncompromised safety by avoiding double-strand DNA breaks. GMP-compliant manufacturing ensures scalable, cost-effective production with high purity and uniformity. Antion’s fully validated assets and expertise provide a robust foundation for developing broad, safe, and effective next-generation cell and gene therapies, setting new industry standards in multiplex gene modulation and engineered cell products